6216-65-5

Usage

Uses

Used in Pharmaceutical Industry:
CBZ-L-VALINOL is used as a reagent for facilitating chemical reactions in the synthesis of various pharmaceuticals. Its stereospecific nature allows for precise control over the outcome of these reactions, which is crucial in the development of new and effective drugs.
Used in Chemical Research:
In the realm of chemical research, CBZ-L-VALINOL is employed as a reagent to assist in the exploration of new chemical pathways and the discovery of novel compounds. Its stability and effectiveness in reactions that require stereospecific organic substances make it a valuable asset in advancing scientific knowledge and innovation.

Upstream product

• 1149-26-4 (S)-N-(benzyloxycarbonyl)valine 
• 24210-19-3 methyl (2S)-3-methyl-[(benzyloxy)carbonylamino]butanoate 
• 24850-33-7 allyltributylstanane 
• 111061-31-5 1-phenoxy-1-trimethylsilyloxyethene 
• 2026-48-4 (S)-valinol 
• 501-53-1 benzyl chloroformate 
• 60-29-7 diethyl ether 
• 67729-33-3 C₁₈H₂₅NO₆ 
• 41445-88-9 Z-Val-OCO₂ⁱBu 
• 91285-94-8 O-benzyl S-(pyridin-2-yl)carbonothioate 
• 72-18-4 L-valine 
• 119153-86-5 C₁₆H₂₁NO₆ 
• 13139-17-8 N-(Benzyloxycarbonyloxy)succinimide 
• 3496-11-5 2,5-dioxopyrrolidin-1-yl (2S)-2-(((benzyloxy)carbonyl)amino)-3-methylbutanoate 

Downstream Products

• 142056-18-6 Z-Val-Ψ(CH2O)Gly-OCH3 
• 137719-71-2 (S)-2-<(benzyloxycarbonyl)amino>-3-methylbutyl ethanethioate 
• 77877-19-1 N-isopropyl oxazolidinone 
• 148028-26-6 (S)-1-allyl-4-isopropyl-2-oxazolidinone 
• 1149-26-4 (S)-N-(benzyloxycarbonyl)valine 
• 699020-16-1 N-{(1S)-2-methyl-1-[(phenylmethoxy)methyl]propyl}-(phenylmethoxy)carboxamide 
• 138754-84-4 N-benzyloxycarbonyl-L-valinal 
• 1087271-39-3 (S)-N-Cbz-2-isopropylaziridine 
• 1169199-22-7 Cbz-Val-ψ[CH2SO2]-F 
• 477808-39-2 (S)-2-benzyloxycarbonylamino-3-methylbutane-1-sulfonyl chloride 
• 1449512-60-0 (S)-(2-methyl-1-nitromethylpropyl)carbamic acid benzyl ester 
• 1638689-28-7 C₁₆H₂₀N₄O₄ 
• 1638689-57-2 C₂₆H₃₁N₅O₅ 
• 149356-88-7 (S)-benzyl (1-(1H-imidazol-2-yl)-2-methylpropyl)carbamate 

Relevant academic research and scientific papers

O-Alkyl S-(Pyridin-2-yl)carbonothiolates: Operationally Simple and Highly Nitrogen-Selective Reagents for Alkoxy Carbonylation of Amino Groups

Amino groups are selectively protected in good yields by reaction with O-Alkyl S-(pyridin-2-yl)carbonothiolates in an appropriate solvent at room temperature in air. Even glucosamine, which contains multiple hydroxyl groups, is selectively N-protected in methanol.

Synthetic method of key intermediate Tuv of natural anti-cancer drug Tubulysins

The invention belongs to the technical field of chemical synthesis, and particularly relates to a synthesis method of a key intermediate Tuv of a natural anti-cancer drug Tubulysins. With L-valinol (1) which is cheap and easy to obtain as a raw material,

Total synthesis of tubulysin U and N14-desacetoxytubulysin H

A concise and efficient procedure for the total synthesis of tubulysin U and N14-desacetoxytubulysin H has been developed with high stereoselectivity on a gram scale. This synthesis features an elegant cascade one-pot process to install the challenging th

FUMAGILLOL COMPOUNDS AND METHODS OF MAKING AND USING SAME

Disclosed herein, in part, are fumagillol compounds and methods of use in treating medical disorders, such as obesity. Pharmaceutical compositions and methods of making fumagillol compounds are provided. The compounds are contemplated to have activity against methionyl aminopeptidase 2.

Potent and Selective Tetrahydroisoquinoline Kappa Opioid Receptor Antagonists of Lead Compound (3 R)-7-Hydroxy- N-[(1 S)-2-methyl-1-(piperidin-1-ylmethyl)propyl]-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (PDTic)

Past studies have shown that it has been difficult to discover and develop potent and selective κ opioid receptor antagonists, particularly compounds having potential for clinical development. In this study, we present a structure-activity relationship (SAR) study of a recently discovered new class of tetrahydroisoquinoline κ opioid receptor antagonists which led to (3R)-7-hydroxy-N-{(1S)-2-methyl-1-[(-4-methylpiperidine-1-yl)methyl]propyl}-1,2,3,4-tetrahydroisoquinoline-3-carboxamide (12) (4-Me-PDTic). Compound 12 had a Ke = 0.37 nM in a [35S]GTPγS binding assay and was 645- and >8100-fold selective for the κ relative to the μ and δ opioid receptors, respectively. Calculated log BB and CNS (central nervous system) multiparameter optimization (MPO) and low molecular weight values all predict that 12 will penetrate the brain, and pharmacokinetic studies in rats show that 12 does indeed penetrate the brain.

Discovery of (Dihydro)pyrazine N-Oxides via Genome Mining in Pseudomonas

Overexpression of the Pseudomonas virulence factor (pvf) biosynthetic operon led to the identification of a family of pyrazine N-oxides (PNOs), including a novel dihydropyrazine N,N′-dioxide (dPNO) metabolite. The nonribosomal peptide synthetase responsib

Discovery of Peptidomimetic Antibody-Drug Conjugate Linkers with Enhanced Protease Specificity

Antibody-drug conjugates (ADCs) have become an important therapeutic modality for oncology, with three approved by the FDA and over 60 others in clinical trials. Despite the progress, improvements in ADC therapeutic index are desired. Peptide-based ADC linkers that are cleaved by lysosomal proteases have shown sufficient stability in serum and effective payload-release in targeted cells. If the linker can be preferentially hydrolyzed by tumor-specific proteases, safety margin may improve. However, the use of peptide-based linkers limits our ability to modulate protease specificity. Here we report the structure-guided discovery of novel, nonpeptidic ADC linkers. We show that a cyclobutane-1,1-dicarboxamide-containing linker is hydrolyzed predominantly by cathepsin B while the valine-citrulline dipeptide linker is not. ADCs bearing the nonpeptidic linker are as efficacious and stable in vivo as those with the dipeptide linker. Our results strongly support the application of the peptidomimetic linker and present new opportunities for improving the selectivity of ADCs.

TETRAHYDROISOQUINOLINE KAPPA OPIOID ANTAGONISTS

Potent opioid receptor antagonists of formula (I) and their use as pharmacotherapies for treating depression, anxiety, schizophrenia, eating disorders, and addiction to cocaine, methamphetamine, nicotine, alcohol, and opiates are disclosed. More specifically, the disclosure provides potent and selective kappa opioid receptor antagonist compounds, pharmaceutical compositions of those compounds and uses of those compounds to ameliorate or treat addictions, eating disorders, etc.

Synthesis and evaluation of chirally defined side chain variants of 7-chloro-4-aminoquinoline to overcome drug resistance in malaria chemotherapy

A novel 4-aminoquinoline derivative [(S)-7-chloro-N-(4-methyl-1-(4-methyl-piperazin-1-yl)pentan-2-yl)-quinolin-4-amine triphosphate] exhibiting curative activity against chloroquine-resistant malaria parasites has been identified for preclinical development as a blood schizonticidal agent. The lead molecule selected after detailed structure-activity relationship (SAR) studies has good solid-state properties and promising activity against in vitro and in vivo experimental malaria models. The in vitro absorption, distribution, metabolism, and excretion (ADME) parameters indicate a favorable drug-like profile.

A Simple, efficient, Catalyst-Free and Solvent-Less Microwave-Assisted process for N-Cbz Protection of Several amines

A simple, green and chemo-selective method for the N-benzyloxycarbonylation of amines, β-amino alcohols, α-amino esters and sulfonamides has been developed under microwave irradiation. Good to excellent yields of the N-benzyloxy-carbamates compounds were obtained in short times without any side products.